Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Leucoside is a natural flavonoid isolated from tea seed extract (*Camellia* species) that functions as a Toll-like receptor 4 (TLR4) inhibitor. It exerts its anti-inflammatory effects by competitively binding to conserved positively charged residues (specifically Lys263 and Arg337) within the B patch of TLR4. This binding creates a spatial barrier that prevents the association of myeloid differentiation protein 2 (MD2) with TLR4, thereby blocking the formation of the active TLR4-MD2 signaling complex. Consequently, leucoside suppresses the activation of the nuclear factor kappa-B (NF-κB) pathway and the subsequent release of pro-inflammatory cytokines. It is primarily being investigated for its potential to treat sepsis and other TLR4-mediated inflammatory conditions by reducing systemic inflammation and organ damage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on leucoside.